{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,31]],"date-time":"2025-12-31T11:53:31Z","timestamp":1767182011663,"version":"build-2238731810"},"update-to":[{"DOI":"10.1371\/journal.ppat.1007701","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2019,4,11]],"date-time":"2019-04-11T00:00:00Z","timestamp":1554940800000}}],"reference-count":76,"publisher":"Public Library of Science (PLoS)","issue":"4","license":[{"start":{"date-parts":[[2019,4,1]],"date-time":"2019-04-01T00:00:00Z","timestamp":1554076800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100009053","name":"DBT India Alliance","doi-asserted-by":"publisher","award":["Senior Fellowship IA\/S\/14\/1\/501307"],"award-info":[{"award-number":["Senior Fellowship IA\/S\/14\/1\/501307"]}],"id":[{"id":"10.13039\/501100009053","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.plospathogens.org"],"crossmark-restriction":false},"short-container-title":["PLoS Pathog"],"DOI":"10.1371\/journal.ppat.1007701","type":"journal-article","created":{"date-parts":[[2019,4,1]],"date-time":"2019-04-01T13:35:23Z","timestamp":1554125723000},"page":"e1007701","update-policy":"https:\/\/doi.org\/10.1371\/journal.ppat.corrections_policy","source":"Crossref","is-referenced-by-count":8,"title":["Mutational pathway maps and founder effects define the within-host spectrum of hepatitis C virus mutants resistant to drugs"],"prefix":"10.1371","volume":"15","author":[{"given":"Rubesh","family":"Raja","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aditya","family":"Pareek","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8903-8774","authenticated-orcid":true,"given":"Kapil","family":"Newar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2145-9828","authenticated-orcid":true,"given":"Narendra M.","family":"Dixit","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2019,4,1]]},"reference":[{"key":"ref1","year":"2016"},{"issue":"9973","key":"ref2","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1016\/S0140-6736(14)61228-9","article-title":"Virological response after 6 week triple-drug regimens for hepatitis C: a proof-of-concept phase 2A cohort study","volume":"385","author":"A Kohli","year":"2015","journal-title":"Lancet"},{"issue":"2","key":"ref3","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/S2468-1253(16)30015-2","article-title":"Efficacy and safety of 3-week response-guided triple direct-acting antiviral therapy for chronic hepatitis C infection: a phase 2, open-label, proof-of-concept study","volume":"1","author":"G Lau","year":"2016","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"5","key":"ref4","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1053\/j.gastro.2017.02.022","article-title":"Response-guided duration of direct acting antiviral therapy for chronic hepatitis C: back to the future?","volume":"152","author":"A Aghemo","year":"2017","journal-title":"Gastroenterology"},{"issue":"8","key":"ref5","doi-asserted-by":"crossref","first-page":"1922","DOI":"10.1073\/pnas.1610197114","article-title":"Quantifying antiviral activity optimizes drug combinations against hepatitis C virus infection","volume":"114","author":"Y Koizumi","year":"2017","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"23","key":"ref6","doi-asserted-by":"crossref","first-page":"E4524","DOI":"10.1073\/pnas.1704531114","article-title":"Inhibitors of hepatitis C virus entry may be potent ingredients of optimal drug combinations","volume":"114","author":"P Padmanabhan","year":"2017","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"23","key":"ref7","doi-asserted-by":"crossref","first-page":"E4527","DOI":"10.1073\/pnas.1705234114","article-title":"Reply to Padmanabhan and Dixit: Hepatitis C virus entry inhibitors for optimally boosting direct-acting antiviral-based treatments","volume":"114","author":"H Ohashi","year":"2017","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"6","key":"ref8","doi-asserted-by":"crossref","first-page":"e1004040","DOI":"10.1371\/journal.pcbi.1004040","article-title":"Rational design and adaptive management of combination therapies for hepatitis C virus infection","volume":"11","author":"R Ke","year":"2015","journal-title":"PLoS Comput Biol"},{"issue":"2","key":"ref9","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1016\/j.jhep.2015.09.011","article-title":"The importance of resistance to direct antiviral drugs in HCV infection in clinical practice","volume":"64","author":"C. Sarrazin","year":"2016","journal-title":"J Hepatol"},{"issue":"6","key":"ref10","doi-asserted-by":"crossref","first-page":"e1004854","DOI":"10.1371\/journal.ppat.1004854","article-title":"Successes and challenges on the road to cure hepatitis C","volume":"11","author":"SM Horner","year":"2015","journal-title":"PLoS Pathog"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.antiviral.2017.02.014","article-title":"Current therapy for chronic hepatitis C: The role of direct-acting antivirals","volume":"142","author":"G Li","year":"2017","journal-title":"Antiviral Res"},{"issue":"11","key":"ref12","doi-asserted-by":"crossref","first-page":"5746","DOI":"10.3390\/v7112902","article-title":"Resistance of hepatitis C virus to inhibitors: complexity and clinical implications","volume":"7","author":"C Perales","year":"2015","journal-title":"Viruses"},{"issue":"12","key":"ref13","doi-asserted-by":"crossref","first-page":"i329","DOI":"10.1093\/bioinformatics\/btu295","article-title":"Accurate viral population assembly from ultra-deep sequencing data","volume":"30","author":"S Mangul","year":"2014","journal-title":"Bioinformatics"},{"issue":"5","key":"ref14","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1002\/hep4.1050","article-title":"Sequencing of hepatitis C virus for detection of resistance to direct-acting antiviral therapy: A systematic review","volume":"1","author":"SR Bartlett","year":"2017","journal-title":"Hepatol Commun."},{"issue":"2","key":"ref15","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1053\/j.gastro.2006.06.007","article-title":"Hepatitis C virus genotypes and viral concentrations in participants of a general population survey in the United States","volume":"131","author":"OV Nainan","year":"2006","journal-title":"Gastroenterology"},{"issue":"30","key":"ref16","doi-asserted-by":"crossref","first-page":"E7139","DOI":"10.1073\/pnas.1805267115","article-title":"Superinfection and cure of infected cells as mechanisms for hepatitis C virus adaptation and persistence","volume":"115","author":"R Ke","year":"2018","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"8","key":"ref17","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1038\/nrgastro.2015.97","article-title":"Modelling hepatitis C therapy\u2014predicting effects of treatment","volume":"12","author":"AS Perelson","year":"2015","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"30","key":"ref18","doi-asserted-by":"crossref","first-page":"30ra2","DOI":"10.1126\/scitranslmed.3000544","article-title":"Rapid emergence of protease inhibitor resistance in hepatitis C virus","volume":"2","author":"L Rong","year":"2010","journal-title":"Sci Transl Med"},{"issue":"4","key":"ref19","doi-asserted-by":"crossref","first-page":"e1000745","DOI":"10.1371\/journal.pcbi.1000745","article-title":"A multi-variant, viral dynamic model of genotype 1 HCV to assess the in vivo evolution of protease-inhibitor resistant variants","volume":"6","author":"BS Adiwijaya","year":"2010","journal-title":"PLoS Comput Biol"},{"issue":"7","key":"ref20","doi-asserted-by":"crossref","first-page":"e1006335","DOI":"10.1371\/journal.pcbi.1006335","article-title":"Modelling how responsiveness to interferon improves interferon-free treatment of hepatitis C virus infection","volume":"14","author":"V Venugopal","year":"2018","journal-title":"PLoS Comput Biol"},{"issue":"5","key":"ref21","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1097\/00002030-199805000-00006","article-title":"The frequency of resistant mutant virus before antiviral therapy","volume":"12","author":"RM Ribeiro","year":"1998","journal-title":"AIDS"},{"issue":"19","key":"ref22","doi-asserted-by":"crossref","first-page":"10230","DOI":"10.1128\/JVI.01010-10","article-title":"Estimating frequencies of minority nevirapine-resistant strains in chronically HIV-1-infected individuals naive to nevirapine by using stochastic simulations and a mathematical model","volume":"84","author":"S Gadhamsetty","year":"2010","journal-title":"J Virol"},{"issue":"27","key":"ref23","doi-asserted-by":"crossref","first-page":"11199","DOI":"10.1073\/pnas.1107729108","article-title":"Majority of CD4+ T cells from peripheral blood of HIV-1-infected individuals contain only one HIV DNA molecule","volume":"108","author":"L Josefsson","year":"2011","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"2","key":"ref24","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1128\/JVI.01304-06","article-title":"Mathematical modeling of subgenomic hepatitis C virus replication in Huh-7 cells","volume":"81","author":"H Dahari","year":"2007","journal-title":"J Virol"},{"issue":"8","key":"ref25","doi-asserted-by":"crossref","first-page":"e1002881","DOI":"10.1371\/journal.ppat.1002881","article-title":"Quantifying the diversification of hepatitis C virus (HCV) during primary infection: estimates of the in vivo mutation rate","volume":"8","author":"RM Ribeiro","year":"2012","journal-title":"PLoS Pathog"},{"issue":"8","key":"ref26","doi-asserted-by":"crossref","first-page":"e1003561","DOI":"10.1371\/journal.ppat.1003561","article-title":"Replication vesicles are load- and choke-points in the hepatitis C virus lifecycle","volume":"9","author":"M Binder","year":"2013","journal-title":"PLoS Pathog"},{"issue":"2","key":"ref27","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1016\/j.virol.2012.08.046","article-title":"The specific infectivity of hepatitis C virus changes through its life cycle","volume":"433","author":"SJ Keum","year":"2012","journal-title":"Virology"},{"issue":"4","key":"ref28","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.1053\/j.gastro.2008.12.060","article-title":"A mathematical model of hepatitis C virus dynamics in patients with high baseline viral loads or advanced liver disease","volume":"136","author":"H Dahari","year":"2009","journal-title":"Gastroenterology"},{"issue":"5386","key":"ref29","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1126\/science.282.5386.103","article-title":"Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-alpha therapy","volume":"282","author":"AU Neumann","year":"1998","journal-title":"Science"},{"issue":"7019","key":"ref30","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1038\/nature03153","article-title":"Modelling how ribavirin improves interferon response rates in hepatitis C virus infection","volume":"432","author":"NM Dixit","year":"2004","journal-title":"Nature"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"3872","DOI":"10.1038\/ncomms4872","article-title":"Emergent properties of the interferon-signalling network may underlie the success of hepatitis C treatment.","volume":"5","author":"P Padmanabhan","year":"2014","journal-title":"Nat Commun"},{"issue":"5","key":"ref32","doi-asserted-by":"crossref","first-page":"e0155869","DOI":"10.1371\/journal.pone.0155869","article-title":"Geno2pheno[HCV]\u2014A web-based interpretation system to support hepatitis C treatment decisions in the era of direct-acting antiviral agents","volume":"11","author":"P Kalaghatgi","year":"2016","journal-title":"PLoS One"},{"issue":"6","key":"ref33","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1086\/591141","article-title":"Natural prevalence of hepatitis C virus variants with decreased sensitivity to NS3.4A protease inhibitors in treatment-naive subjects","volume":"198","author":"DJ Bartels","year":"2008","journal-title":"J Infect Dis"},{"issue":"31","key":"ref34","doi-asserted-by":"crossref","first-page":"22619","DOI":"10.1074\/jbc.M610207200","article-title":"Phenotypic and structural analyses of hepatitis C virus NS3 protease Arg155 variants: sensitivity to telaprevir (VX-950) and interferon alpha","volume":"282","author":"Y Zhou","year":"2007","journal-title":"J Biol Chem"},{"issue":"24","key":"ref35","doi-asserted-by":"crossref","first-page":"13354","DOI":"10.1128\/JVI.02465-13","article-title":"Evasion of superinfection exclusion and elimination of primary viral RNA by an adapted strain of hepatitis C virus","volume":"87","author":"B Webster","year":"2013","journal-title":"J Virol"},{"issue":"51","key":"ref36","doi-asserted-by":"crossref","first-page":"20509","DOI":"10.1073\/pnas.1105797108","article-title":"Contribution of a mutational bias in hepatitis C virus replication to the genetic barrier in the development of drug resistance","volume":"108","author":"MH Powdrill","year":"2011","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"4","key":"ref37","doi-asserted-by":"crossref","first-page":"2105","DOI":"10.1128\/AAC.02068-13","article-title":"Ultradeep sequencing study of chronic hepatitis C virus genotype 1 infection in patients treated with daclatasvir, peginterferon, and ribavirin","volume":"58","author":"E Murakami","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"issue":"4","key":"ref38","doi-asserted-by":"crossref","first-page":"e1004064","DOI":"10.1371\/journal.ppat.1004064","article-title":"A quantitative high-resolution genetic profile rapidly identifies sequence determinants of hepatitis C viral fitness and drug sensitivity","volume":"10","author":"H Qi","year":"2014","journal-title":"PLoS Pathog"},{"key":"ref39","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1111\/liv.13638","article-title":"Treatment of hepatitis C: Results in real life","volume":"38","author":"C. Hezode","year":"2018","journal-title":"Liver Int"},{"key":"ref40","article-title":"Submission to the United Nations secretary-general\u2019s high-level panel on access to medicines","author":"G. Alton","year":"2016","journal-title":"Gilead Sciences"},{"key":"ref41","unstructured":"UNITAID. Hepatitis C medicines: technology and market landscape\u2013update; (<ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/unitaid.org\/assets\/HCV_Meds_Landscape_Feb2015-1.pdf\" xlink:type=\"simple\">https:\/\/unitaid.org\/assets\/HCV_Meds_Landscape_Feb2015-1.pdf<\/ext-link>). 2015."},{"issue":"1","key":"ref42","doi-asserted-by":"crossref","first-page":"10233","DOI":"10.1038\/s41598-017-09776-z","article-title":"The paradox of highly effective sofosbuvir-based combination therapy despite slow viral decline: can we still rely on viral kinetics?","volume":"7","author":"THT Nguyen","year":"2017","journal-title":"Sci Rep"},{"issue":"9","key":"ref43","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1111\/imcb.12161","article-title":"Modeling how reversal of immune exhaustion elicits cure of chronic hepatitis C after the end of treatment with direct-acting antiviral agents","volume":"96","author":"S Baral","year":"2018","journal-title":"Immunol Cell Biol"},{"issue":"10","key":"ref44","doi-asserted-by":"crossref","first-page":"3991","DOI":"10.1073\/pnas.1203110110","article-title":"Modeling shows that the NS5A inhibitor daclatasvir has two modes of action and yields a shorter estimate of the hepatitis C virus half-life","volume":"110","author":"J Guedj","year":"2013","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"8","key":"ref45","doi-asserted-by":"crossref","first-page":"1789","DOI":"10.1007\/s11538-012-9736-y","article-title":"Modeling quasispecies and drug resistance in hepatitis C patients treated with a protease inhibitor","volume":"74","author":"L Rong","year":"2012","journal-title":"Bull Math Biol"},{"issue":"1","key":"ref46","doi-asserted-by":"crossref","first-page":"e1002339","DOI":"10.1371\/journal.pcbi.1002339","article-title":"A viral dynamic model for treatment regimens with direct-acting antivirals for chronic hepatitis C infection","volume":"8","author":"BS Adiwijaya","year":"2012","journal-title":"PLoS Comput Biol"},{"issue":"12","key":"ref47","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1016\/j.tim.2006.10.001","article-title":"Stochastic or deterministic: what is the effective population size of HIV-1?","volume":"14","author":"RD Kouyos","year":"2006","journal-title":"Trends Microbiol"},{"issue":"1","key":"ref48","doi-asserted-by":"crossref","first-page":"e14531","DOI":"10.1371\/journal.pone.0014531","article-title":"Taking multiple infections of cells and recombination into account leads to small within-host effective-population-size estimates of HIV-1","volume":"6","author":"R Balagam","year":"2011","journal-title":"PLoS One"},{"issue":"9","key":"ref49","doi-asserted-by":"crossref","first-page":"e1002684","DOI":"10.1371\/journal.pcbi.1002684","article-title":"Stochastic simulations suggest that HIV-1 survives close to its error threshold.","volume":"8","author":"K Tripathi","year":"2012","journal-title":"PLoS Comput Biol"},{"key":"ref50","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1038\/s41551-017-0126-5","article-title":"Multiplexed enrichment of rare DNA variants via sequence-selective and temperature-robust amplification","volume":"1","author":"LR Wu","year":"2017","journal-title":"Nat Biomed Eng"},{"issue":"18","key":"ref51","doi-asserted-by":"crossref","first-page":"1827","DOI":"10.1056\/NEJMoa0806104","article-title":"Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection","volume":"360","author":"JG McHutchison","year":"2009","journal-title":"N Engl J Med"},{"issue":"6","key":"ref52","doi-asserted-by":"crossref","first-page":"1924","DOI":"10.1002\/hep.24594","article-title":"Genotypic and phenotypic analysis of variants resistant to hepatitis C virus nonstructural protein 5A replication complex inhibitor BMS-790052 in humans: in vitro and in vivo correlations","volume":"54","author":"RA Fridell","year":"2011","journal-title":"Hepatology"},{"issue":"6","key":"ref53","doi-asserted-by":"crossref","first-page":"1956","DOI":"10.1002\/hep.24609","article-title":"Multiple ascending dose study of BMS-790052, a nonstructural protein 5A replication complex inhibitor, in patients infected with hepatitis C virus genotype 1","volume":"54","author":"RE Nettles","year":"2011","journal-title":"Hepatology"},{"issue":"1","key":"ref54","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.jhep.2016.09.001","article-title":"EASL Recommendations on treatment of hepatitis C 2016","volume":"66","year":"2017","journal-title":"J Hepatol"},{"issue":"1","key":"ref55","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1053\/j.gastro.2016.04.003","article-title":"Hepatitis C virus resistance to direct-acting antiviral drugs in interferon-free regimens","volume":"151","author":"JM Pawlotsky","year":"2016","journal-title":"Gastroenterology"},{"issue":"5","key":"ref56","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1111\/apt.14478","article-title":"Viral kinetics analysis and virological characterization of treatment failures in patients with chronic hepatitis C treated with sofosbuvir and an NS5A inhibitor","volume":"47","author":"S Fourati","year":"2018","journal-title":"Aliment Pharmacol Ther"},{"issue":"1","key":"ref57","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1186\/s12879-017-2817-7","article-title":"Prevalence of naturally occurring NS5A resistance-associated substitutions in patients infected with hepatitis C virus subtype 1a, 1b, and 3a, co-infected or not with HIV in Brazil.","volume":"17","author":"F Malta","year":"2017","journal-title":"BMC Infect Dis"},{"issue":"6","key":"ref58","doi-asserted-by":"crossref","first-page":"066006","DOI":"10.1088\/1478-3975\/12\/6\/066006","article-title":"Empirical fitness models for hepatitis C virus immunogen design","volume":"12","author":"GR Hart","year":"2015","journal-title":"Phys Biol"},{"issue":"3","key":"ref59","doi-asserted-by":"crossref","first-page":"e1000305","DOI":"10.1371\/journal.pcbi.1000305","article-title":"Timing the emergence of resistance to anti-HIV drugs with large genetic barriers","volume":"5","author":"P Arora","year":"2009","journal-title":"PLoS Comput Biol"},{"issue":"9","key":"ref60","doi-asserted-by":"crossref","first-page":"4591","DOI":"10.1128\/JVI.02144-06","article-title":"Analysis of hepatitis C virus superinfection exclusion by using novel fluorochrome gene-tagged viral genomes","volume":"81","author":"T Schaller","year":"2007","journal-title":"J Virol"},{"issue":"8","key":"ref61","doi-asserted-by":"crossref","first-page":"3693","DOI":"10.1128\/JVI.01748-06","article-title":"Superinfection exclusion in cells infected with hepatitis C virus","volume":"81","author":"DM Tscherne","year":"2007","journal-title":"J Virol"},{"issue":"1","key":"ref62","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1128\/JVI.01047-12","article-title":"Rapid intracellular competition between hepatitis C viral genomes as a result of mitosis","volume":"87","author":"B Webster","year":"2013","journal-title":"J Virol"},{"key":"ref63","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/S0168-8278(13)00228-6","article-title":"Altered HCV specific T cell immunity very early in interferon free HCV daa therapy","volume":"58","author":"L Barrett","year":"2013","journal-title":"J Hepatol"},{"issue":"3","key":"ref64","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1016\/j.jhep.2014.05.043","article-title":"Restoration of HCV-specific CD8+ T cell function by interferon-free therapy","volume":"61","author":"B Martin","year":"2014","journal-title":"J Hepatol"},{"issue":"9","key":"ref65","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1111\/jvh.12702","article-title":"Augmentation of hepatitis C virus-specific immunity and sustained virologic response","volume":"24","author":"S Shrivastava","year":"2017","journal-title":"J Viral Hepat"},{"key":"ref66","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1016\/j.jhep.2012.10.005","article-title":"Innate immunity and HCV","volume":"58","author":"MH Heim","year":"2013","journal-title":"J Hepatol"},{"issue":"1","key":"ref67","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.virol.2005.09.024","article-title":"The interferon response circuit: Induction and suppression by pathogenic viruses","volume":"344","author":"O Haller","year":"2006","journal-title":"Virology"},{"issue":"6","key":"ref68","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1016\/j.chom.2009.11.004","article-title":"Hepatitis C virus blocks interferon effector function by inducing protein kinase R phosphorylation","volume":"6","author":"U Garaigorta","year":"2009","journal-title":"Cell Host Microbe"},{"issue":"21","key":"ref69","doi-asserted-by":"crossref","first-page":"13374","DOI":"10.1073\/pnas.212514799","article-title":"Error catastrophe and antiviral strategy","volume":"99","author":"M. Eigen","year":"2002","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"6","key":"ref70","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/0966-842X(96)20011-3","article-title":"On the nature of virus quasispecies","volume":"4","author":"M. Eigen","year":"1996","journal-title":"Trends Microbiol"},{"issue":"25","key":"ref71","doi-asserted-by":"crossref","first-page":"2340","DOI":"10.1021\/j100540a008","article-title":"Exact stochastic simulation of couple chemical reactions","volume":"81","author":"DT Gillesple","year":"1977","journal-title":"J Phys Chem"},{"issue":"6","key":"ref72","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1038\/clpt.2010.35","article-title":"A comprehensive hepatitis C viral kinetic model explaining cure","volume":"87","author":"E Snoeck","year":"2010","journal-title":"Clin Pharmacol Ther"},{"issue":"6","key":"ref73","doi-asserted-by":"crossref","first-page":"1801","DOI":"10.1002\/hep.24272","article-title":"Second-phase hepatitis C virus RNA decline during telaprevir-based therapy increases with drug effectiveness: implications for treatment duration","volume":"53","author":"J Guedj","year":"2011","journal-title":"Hepatology"},{"issue":"3","key":"ref74","doi-asserted-by":"crossref","first-page":"e1002959","DOI":"10.1371\/journal.pcbi.1002959","article-title":"Analysis of hepatitis C virus decline during treatment with the protease inhibitor danoprevir using a multiscale model","volume":"9","author":"L Rong","year":"2013","journal-title":"PLoS Comput Biol"},{"issue":"12","key":"ref75","doi-asserted-by":"crossref","first-page":"e1002307","DOI":"10.1371\/journal.pcbi.1002307","article-title":"Mathematical model of viral kinetics in vitro estimates the number of E2-CD81 complexes necessary for hepatitis C virus entry","volume":"7","author":"P Padmanabhan","year":"2011","journal-title":"PLoS Comput Biol"},{"issue":"17","key":"ref76","doi-asserted-by":"crossref","first-page":"2457","DOI":"10.1093\/bioinformatics\/btr401","article-title":"StochKit2: software for discrete stochastic simulation of biochemical systems with events","volume":"27","author":"KR Sanft","year":"2011","journal-title":"Bioinformatics"}],"updated-by":[{"DOI":"10.1371\/journal.ppat.1007701","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2019,4,11]],"date-time":"2019-04-11T00:00:00Z","timestamp":1554940800000}}],"container-title":["PLOS Pathogens"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.ppat.1007701","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,9]],"date-time":"2020-05-09T04:43:55Z","timestamp":1588999435000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.ppat.1007701"}},"subtitle":[],"editor":[{"given":"Robert","family":"Belshaw","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2019,4,1]]},"references-count":76,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2019,4,1]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.ppat.1007701","relation":{},"ISSN":["1553-7374"],"issn-type":[{"value":"1553-7374","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,4,1]]}}}